The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management
Second, due to the heterogeneity of the TME, combining multiple response mechanisms to achieve the optimal therapeutic effect has become a hot topic in subsequent research
Ingredient Acetyl-L-Carnitine Dicalcium Phosphate Tocopherol Antioxidants
A value drifting toward zero signals aggregation and inconsistent brightening outcomes across the batch
Since then, multiple animal and in vitro studies confirmed GHK-Cus ability to improve wound healing and tissue regeneration [ 19 , 20 ]
and (3) grades 3 and 4 (severe liver injury): ALT levels are elevated to 5 ULN, or ALP and GGT levels are elevated to 5 ULN
